Fig. 1
Outcomes of 44 paediatric patients with MLL-r AML undergoing HSCT: (A) overall survival (OS), (B) event-free survival (EFS), and (C) cumulative incidence of relapse (CIR)
Fig. 1 | BMC Cancer
Outcomes of 44 paediatric patients with MLL-r AML undergoing HSCT: (A) overall survival (OS), (B) event-free survival (EFS), and (C) cumulative incidence of relapse (CIR)